Business Context and Reporting Period
Creative Medical Technology Holdings, Inc. (CELZ) filed a Form 8-K Current Report dated June 30, 2026. The filing details a material definitive agreement involving a warrant exercise inducement and a compensatory arrangement for the Chief Executive Officer.
Key Financial Metrics and Transaction Details
- Transaction Proceeds: Approximately $4.5 million in aggregate gross proceeds from the exercise of existing warrants.
- Use of Proceeds: Working capital and general corporate purposes.
- Transaction Costs: Financial advisory fee of 8% of gross proceeds plus $50,000 in reimbursed legal expenses.
- Executive Compensation: A $100,000 bonus approved for CEO Timothy Warbington.
The filing does not provide specific values for revenue, net profit, operating cash flow, margins, total debt, or liquidity ratios for the reporting period.
Material Changes and Transaction Structure
The Company entered into inducement letters with holders of 2,790,340 existing warrants (originally issued October 29, 2025). Key changes include:
- Exercise Price Reduction: The exercise price for existing warrants was reduced from $2.86 to $1.60 per share.
- New Securities Issued: Holders received new "Inducement Warrants" to purchase 5,580,680 shares of common stock at $1.60 per share.
- Conditions: Inducement Warrants are exercisable for five years following stockholder approval required by Nasdaq rules.
Outlook, Risks, and Contingencies
- Regulatory Requirement: The Inducement Warrants cannot be exercised until the Company obtains stockholder approval for the underlying shares.
- Registration Obligation: The Company agreed to file a resale registration statement on Form S-3 within 30 days of closing.
- Unregistered Securities: The Inducement Warrants were issued in a private placement under Section 4(a)(2) of the Securities Act and are not currently registered.
Investor Verification Checklist
- Verify the status of the stockholder approval required for the Inducement Warrants to become exercisable.
- Confirm the filing of the Form S-3 resale registration statement within the 30-day window.
- Review the impact of the 8% advisory fee and $50,000 legal reimbursement on the net cash received.
- Assess the dilution impact of the 5,580,680 new Inducement Warrants and the 2,790,340 shares issued upon exercise.